Sunday, February 15, 2026 2/15/2026

Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer

Award Number: R44CA203455
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2016
PERIOD OF PERFORMANCE END DATE: 06/30/2023

Group Awards By:

View Award Description

Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer - Project Summary. The Indicator Cell Assay Platform (iCAP) is an inexpensive blood-based assay that can be used for early detection of disease, disease stage stratification, prognosis and response to therapy for a variety of diseases. The iCAP uses cultured, standardized cells as biosensors, capitalizing on the ability of cells to respond to disease signals present in serum with exquisite sensitivity, as opposed to traditional assays that rely on direct detection of molecules in blood. Developing the iCAP involves exposing cultured cells to serum from normal or diseased subjects, measuring a global differential response pattern, and using it to train a reliable disease classifier based on the expression of a small number of genes. Deploying the iCAP involves measuring only expression of classifier genes using cost-effective tools. We have demonstrated the iCAP by pre- symptomatic detection of disease in an amyotrophic lateral sclerosis mouse model, and early detection of Alzheimer's disease in humans, which we are currently validating. Here, we are developing an iCAP for diagnosis of lung cancer (LC). Blood biomarkers of LC are critically needed for use in combination with existing imaging tools to improve diagnostic accuracy. Our goal is to develop an iCAP for use on patients who have indeterminate pulmonary nodules (IPNs) identified by imaging that cannot be confidently classified as malignant or benign from the data. For clinical utility, the iCAP needs to distinguish malignant from benign nodules with 1) High sensitivity and negative predictive value (NPV) to minimize the number of patients with malignant tumors that have negative test results, and 2) A specificity that will provide economic impact and actionable results for patients correctly identified with benign nodules. We have demonstrated proof of concept for the LC iCAP and achieved 96% NPV, 92% sensitivity and 52% specificity in distinguishing non-small cell lung cancer from benign nodules (with independent samples). Potential for clinical utility is high with low risk of missing malignant tumors (8% FNR), actionable results for 52% of patients with benign nodules, and performance that is better or similar to other assays on the market and in development. For Phase II, we propose to optimize and validate the assay with larger cohorts from independent sites to position us to commercialize the assay as a clinical test. We aim to: 1) Optimize experimental, technical, and computational parameters of the iCAP, 2) Train and test an improved iCAP classifier using optimal conditions, and 3) Validate the classifier with blind independent samples. Our goal is to achieve clinical utility and greater performance than competing tests in development with ≥95% sensitivity and >60% specificity, with >90% NPV. Our ultimate goal is to develop a test that can be offered to patients at the time of finding an IPN by imaging. Our simple blood-based assay will give patients a probability of disease using a continuous variable. We will develop a visual depiction of the data that patients and doctors can use to assess risk and decide treatment. With our collaborator, Dr. Massion, we will work to refine the best clinical approach.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$226 )
2024	2021	PRECYTE INC	10341 WINDSOR VIEW DR	POTOMAC	MD	20854	MONTGOMERY	USA	Cancer Detection and Diagnosis Research	000	4	1/10/2024	NON-COMPETING CONTINUATION	-$226
														Subtotal = -$226

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	PRECYTE INC	401 TERRY AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	4	5/1/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $488,587 )
2021	2021	PRECYTE INC	454 N 34TH ST	SEATTLE	WA	98103	KING	USA	Cancer Detection and Diagnosis Research	000	4	1/27/2021	NON-COMPETING CONTINUATION	$488,587
														Subtotal = $488,587

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	PRECYTE INC	401 TERRY N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	3	9/3/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $509,200 )
2019	2019	PRECYTE INC	401 TERRY N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	3	7/29/2019	NON-COMPETING CONTINUATION	$509,200
														Subtotal = $509,200

Issue Date FY: 2018 ( Subtotal = $996,232 )
2018	2018	PRECYTE INC	401 TERRY N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	2	8/13/2018	COMPETING CONTINUATION	$926,232
2018	2018	PRECYTE INC	401 TERRY N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	001	2	9/10/2018	COMPETING CONTINUATION	$70,000
														Subtotal = $996,232

Grand Total All Awards = $1,993,793

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer

Award Number: R44CA203455

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2016

PERIOD OF PERFORMANCE END DATE: 06/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer